MIP and Superlco launch new SPE for amphetamines

USA-based MIP Technologies AB and Supelco, a division of Sigma-Aldrich Corp, have launched their new SupelMIP product for the selective extraction of amphetamine and related drugs.

According to the firms, it is a fast, selective and highly sensitive solid phase extraction product developed for trace level determinations in forensic, toxicological and pharmaceutical testing. The SPE phase has been evaluated for amphetamine, methamphetamine, phentermine and 3,4-methylenedioxy-N-methylamphetamine (MDMA), most commonly known by the street name ecstasy, as well as its related compounds MDA and MDEA.

"SupelMIP SPE-Amphetamines expand the SupelMIP product portfolio into the drugs of abuse area. The detection levels are in the low part per trillion range, which is far lower than competing extraction phases on the market and makes the SupelMIP product ideal for difficult forensic applications where drug concentrations may be low and sensitivity is critical," said Christine Widstrand, vice president of sales and marketing at MIP.